Decreased Fibrinolysis in Behçet’s Disease

1973 ◽  
Vol 29 (03) ◽  
pp. 610-618 ◽  
Author(s):  
Tova Chajek ◽  
Eta Aronowski ◽  
G Izak
Keyword(s):  
Factor Viii ◽  
Plasminogen Activator ◽  
Behçet’S Disease ◽  
Fibrinolytic Activity ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Fibrinogen Concentration ◽  
Factor Viii Activity ◽  
Fibrinolytic Agents ◽  
Behcet's Disease

SummaryThe coagulation and fibrinolytic systems have been investigated in nine patients suffering from Behçet’s disease. Six of these had thrombophlebitis.The results of these studies revealed markedly elevated fibrinogen concentration and increased factor VIII activity as well as a pronounced decrease in the spontaneous fibrinolytic activity. This latter finding may have resulted from the presence of a potent antiplasmin activity and that of an inhibitor of the plasminogen activator detected in these patients’ sera.It is suggested that decreased fibrinolysis aggravates the thrombotic episodes frequently encountered in Behçet’s disease; accordingly treatment with fibrinolytic agents was found to offer marked benefits.

Coagulation and Fibrinolytic Activity in Behçet's Disease

1991 ◽  
Vol 66 (03) ◽  
pp. 292-294 ◽  
Author(s):  
K K Hampton ◽  
M A Chamberlain ◽  
D K Menon ◽  
J A Davies
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Behçet’S Disease ◽  
Fibrinolytic Activity ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Plasminogen Activator Inhibitor ◽  
Behcet's Disease ◽  
Tissue Plasminogen ◽  
Von Willebrand

SummaryCoagulation and fibrinolytic activities were studied in 18 subjects with Behçet's disease and compared with results from 14 matched control patients suffering from sero-negative arthritis. Significantly higher plasma concentrations (median and range) were found in Behçet's patients for the following variables: fibrinogen 3.7 (1.7-6.9) vs 3.0 (2.0-5.1) g/1, p <0.05; von Willebrand factor antigen, 115 (72-344) vs 74 (60-119)%, p <0.002; plasminogen activator activity (106/ECLT2) 219 (94-329) vs 137 (78-197) units, p <0.002; tissue plasminogen activator inhibitor (t-PA-I) activity, 9.1 (5.5-19.3) vs 5.1 (1.8-12.0) IU/ml, p <0.002; and PAI-1 antigen, 13.9 (4.5-20.9) vs 6.4 (2.4-11.1) ng/ml, p <0.002. Protein C antigen was significantly lower: 97 (70-183) vs 126 (96-220)%, p <0.02. No differences were observed in antithrombin III activity or antigen, factor VIII coagulant activity, fibrinopeptides A and Bβ15-42, plasminogen, α-2-antiplasmin, functional and immunological tissue-plasminogen activator, thrombin-antithrombin complexes and D-dimer. Levels of tissue plasminogen activator inhibitor (activity and antigen) correlated with disease activity while fibrinogen and von Willebrand factor concentrations did not. Seven of the 18 subjects with Behçet's disease had suffered thrombotic events but it was not possible to distinguish these from the 11 patients without thrombosis using the assays performed. The results suggest the abnormal fibrinolytic activity in Behçet's disease is due to increased inhibition of tissue plasminogen activator. No abnormality of coagulation or fibrinolytic activity specific to Behçet's disease was detected.

Urokinase plasminogen activator receptor levels in Behcet's disease

2011 ◽  
Vol 128 (3) ◽  
pp. 274-276 ◽  
Author(s):  
Serhat Birengel ◽  
F. Nilüfer Yalçındağ ◽  
Ali Yalçındağ ◽  
Esra Sahli ◽  
Figen Batıoğlu
Keyword(s):  
Plasminogen Activator ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Urokinase Plasminogen Activator ◽  
Urokinase Plasminogen Activator Receptor ◽  
Behcet's Disease ◽  
Plasminogen Activator Receptor

C0390 Fibrinolytic activity and d-dimer in Behçet's disease

2012 ◽  
Vol 130 ◽  
pp. S145
Author(s):  
Nabil Belfeki ◽  
Monia Smiti Khanfir ◽  
Amira Hamzaoui ◽  
Thouraya Ben Salem ◽  
Hela Baccouche ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Fibrinolytic Activity ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease ◽  
D Dimer

scholarly journals Clinical value of soluble urokinase-type plasminogen activator receptor (SuPAR) as a biomarker of disease activity in Behcet’s disease

2021 ◽  
Vol 29 (4) ◽  
pp. 47-52
Author(s):  
Amal Rizk ◽  
Walaa Abdelfattah ◽  
Arwa Al-Shaarawy ◽  
Nora Elsaid
Keyword(s):  
Disease Activity ◽  
Plasminogen Activator ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Clinical Value ◽  
Urokinase Plasminogen Activator Receptor ◽  
Behcet's Disease ◽  
Supar Level ◽  
Plasminogen Activator Receptor

Background: Behçet's disease (BD) is a chronic multisystemic vasculitic disease of unknown pathogenesis. Diagnosis and disease activity measurement has always been a challenge. Soluble urokinase plasminogen activator receptor (suPAR) is showing an increased utility as a promising diagnostic and prognostic inflammatory biomarker in different systemic inflammatory disorders. Objectives: To study the clinical value of plasma Soluble urokinase plasminogen activator receptor (suPAR) in patients with Behçet's disease, and if it can be used as a measure to disease activity. Methods: According to the International Criteria for Behcet's Disease (ICBD), fifty adult Behçet's disease patients were enrolled in the study, and forty healthy adult subjects were included in a case-control study. An enzyme-linked immunosorbent assay was used to obtain quantitative data. Results: The suPAR level was not statistically different between the patients with BD patients and the controls. No correlation was found between suPAR levels and disease activity (BDFAC). Conclusion: Very few studies analyzed the clinical value of suPAR level in patients with BD and its correlation with disease activity. Our results show that suPAR does not seem to play a role in the disease mechanism of BD.

Sign in / Sign up

Export Citation Format

Share Document